MedTrace Logo

Open-Label, Multicenter Extension Study for Patients Completing Treatment Phase of a Rigel-Sponsored R935788 Studies

NCT00805467 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 624

Last updated 2014-06-25

Study results available
· View outcomes & findings →

Summary

The purpose of this new research study is to gain additional information about how safe and effective R935788 is over a longer period of time.

Conditions

Interventions

DRUG

Fostamatinib Disodium (R935788)

50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD

Sponsors & Collaborators

Principal Investigators

  • Chris O'Brien, MD, PhD · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • United States
  • Belgium
  • Bulgaria
  • Colombia
  • France
  • Germany
  • Italy
  • Mexico
  • Peru
  • Poland
  • Romania

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00805467 on ClinicalTrials.gov